Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$248.68
+0.5%		$255.71
$197.81
▼
$495.55
$33.28B0.311.46 million shs1.18 million shs
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$534.49
+0.3%		$530.87
$393.61
▼
$615.00
$12.35B-0.98339,731 shs187,642 shs
Natera, Inc. stock logo
NTRA
Natera
$328.93
+0.9%		$296.81
$157.43
▼
$343.18
$47.41B1.541.34 million shs798,010 shs
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$203.77
+0.2%		$198.37
$42.18
▼
$224.31
$43.68B1.42.94 million shs1.38 million shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
-4.07%-6.42%+11.89%-12.49%-47.26%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-2.48%-1.75%-0.40%+10.89%+23.95%
Natera, Inc. stock logo
NTRA
Natera
-1.26%-0.47%+4.29%+53.79%+92.08%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-2.08%-3.57%-1.07%+32.16%+402.72%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$248.68
+0.5%		$255.71
$197.81
▼
$495.55
$33.28B0.311.46 million shs1.18 million shs
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$534.49
+0.3%		$530.87
$393.61
▼
$615.00
$12.35B-0.98339,731 shs187,642 shs
Natera, Inc. stock logo
NTRA
Natera
$328.93
+0.9%		$296.81
$157.43
▼
$343.18
$47.41B1.541.34 million shs798,010 shs
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$203.77
+0.2%		$198.37
$42.18
▼
$224.31
$43.68B1.42.94 million shs1.38 million shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
-4.07%-6.42%+11.89%-12.49%-47.26%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-2.48%-1.75%-0.40%+10.89%+23.95%
Natera, Inc. stock logo
NTRA
Natera
-1.26%-0.47%+4.29%+53.79%+92.08%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-2.08%-3.57%-1.07%+32.16%+402.72%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2.88
Moderate Buy$376.6749.33% Upside
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
2.78
Moderate Buy$699.6431.03% Upside
Natera, Inc. stock logo
NTRA
Natera
2.83
Moderate Buy$330.830.72% Upside
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
2.95
Moderate Buy$218.116.83% Upside

Current Analyst Ratings Breakdown

Latest MDGL, NTRA, RVMD, and ALNY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/10/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageHold ➝ Overweight$255.00
9/9/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Stifel Nicolaus logo
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$215.00 ➝ $230.00
9/9/2026
Natera, Inc. stock logo
NTRA
Natera
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$290.00 ➝ $435.00
9/8/2026
Natera, Inc. stock logo
NTRA
Natera
Rothschild & Co Redburn logo
Rothschild & Co Redburn
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$385.00
9/8/2026
Natera, Inc. stock logo
NTRA
Natera
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeOutperform ➝ Buy
9/8/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetHold$230.00 ➝ $260.00
9/8/2026
Natera, Inc. stock logo
NTRA
Natera
Rothschild & Co Redburn logo
Rothschild & Co Redburn
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$385.00
9/2/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$455.00
8/31/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Sanford C. Bernstein logo
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/31/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/31/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
(Data available from 9/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$3.71B9.09$2.73 per share92.27$5.97 per share42.25
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$1.28B9.61N/AN/A$26.54 per share20.12
Natera, Inc. stock logo
NTRA
Natera
$2.31B20.53N/AN/A$12.38 per share26.53
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$11.58M3,778.92N/AN/A$8.44 per share24.19
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$313.75M$5.3846.8926.00N/A15.26%84.93%14.30%10/29/2026 (Estimated)
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$288.28M-$12.89N/A96.21N/A-25.32%-56.65%-25.53%11/3/2026 (Estimated)
Natera, Inc. stock logo
NTRA
Natera
-$208.16M-$1.36N/A32,845.50N/A-7.11%-11.38%-7.87%11/5/2026 (Estimated)
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$1.13B-$8.82N/AN/AN/AN/A-88.20%-57.85%11/4/2026 (Estimated)

Latest MDGL, NTRA, RVMD, and ALNY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Natera, Inc. stock logo
NTRA
Natera
-$0.4939-$0.47+$0.0239-$0.47$661.24 million$752.75 million
8/5/2026Q2 2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$2.04-$3.06-$1.02-$3.06$1.77 millionN/A
7/30/2026Q2 2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$1.63$1.84+$0.21$1.21$1.32 billion$1.29 billion
7/30/2026Q2 2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$2.68-$1.99+$0.69-$1.99$352.13 million$364.25 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
N/AN/AN/AN/AN/A
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
N/AN/AN/AN/AN/A
Natera, Inc. stock logo
NTRA
Natera
N/AN/AN/AN/AN/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
0.75
3.05
2.99
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
0.65
3.20
2.94
Natera, Inc. stock logo
NTRA
Natera
N/A
3.00
2.85
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
0.40
11.38
11.38

Institutional Ownership

CompanyInstitutional Ownership
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
92.97%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
98.50%
Natera, Inc. stock logo
NTRA
Natera
99.90%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
94.34%

Insider Ownership

CompanyInsider Ownership
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
0.86%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
17.60%
Natera, Inc. stock logo
NTRA
Natera
5.05%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
7.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2,770133.81 million132.66 millionOptionable
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
91523.10 million19.04 millionOptionable
Natera, Inc. stock logo
NTRA
Natera
6,140144.14 million136.87 millionOptionable
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
883214.34 million198.05 millionOptionable

Recent News About These Companies

Lorence Kim Sells 17,090 Shares of Revolution Medicines (NASDAQ:RVMD) Stock
September 11 at 6:22 AM  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-rvmd-insider-buying-and-selling-2026-09-11/
Revolution Medicines, Inc. $RVMD Position Trimmed by Tidal Investments LLC
September 11 at 5:19 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-revolution-medicines-inc-rvmd-position-trimmed-by-tidal-investments-llc-2026-09-11/
Insider Selling: Revolution Medicines (NASDAQ:RVMD) Director Sells 17,090 Shares of Stock
September 10 at 7:06 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-selling-revolution-medicines-nasdaq-rvmd-director-sells-17090-shares-of-stock-2026-09-10/
Revolution Medicines, Inc. $RVMD Shares Bought by Arizona State Retirement System
September 10 at 3:11 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-revolution-medicines-inc-rvmd-shares-bought-by-arizona-state-retirement-system-2026-09-10/
California State Teachers Retirement System Boosts Stock Holdings in Revolution Medicines, Inc. $RVMD
September 9 at 3:59 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-california-state-teachers-retirement-system-boosts-stock-holdings-in-revolution-medicines-inc-rvmd-2026-09-09/
Hsbc Holdings PLC Acquires 39,025 Shares of Revolution Medicines, Inc. $RVMD
September 9 at 3:36 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-hsbc-holdings-plc-acquires-39025-shares-of-revolution-medicines-inc-rvmd-2026-09-09/
Revolution Medicines, Inc. $RVMD Shares Purchased by Saudi Central Bank
September 8 at 5:04 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-revolution-medicines-inc-rvmd-shares-purchased-by-saudi-central-bank-2026-09-08/
Readystate Asset Management LP Grows Position in Revolution Medicines, Inc. $RVMD
September 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-readystate-asset-management-lp-grows-position-in-revolution-medicines-inc-rvmd-2026-09-07/
Nykredit A S Purchases New Shares in Revolution Medicines, Inc. $RVMD
September 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-nykredit-a-s-purchases-new-shares-in-revolution-medicines-inc-rvmd-2026-09-06/
Revolution Medicines (RVMD) Stock Looks Overvalued Even After Its Drug Approval
September 5, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/revolution-medicines-rvmd-stock-looks-141319320.html
Raiffeisen Bank International AG Decreases Stake in Revolution Medicines, Inc. $RVMD
September 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-raiffeisen-bank-international-ag-decreases-stake-in-revolution-medicines-inc-rvmd-2026-09-05/
Revolution Medicines (RVMD) Up 6.6% Since Last Earnings Report: Can It Continue?
September 4, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2985294/revolution-medicines-rvmd-up-6-6-since-last-earnings-report-can-it-continue?cid=cs-stocknewsapi-ft-realtime_blog-2985294
Revolution Medicines logo displayed over a laboratory background with a microscope, flasks, and test tubes.
Revolution Medicines Got Its Breakthrough—What Moves It Next?
...
September 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/articles/revolution-medicines-got-its-breakthroughwhat-moves-it-next/
Lorence Kim Sells 56,000 Shares of Revolution Medicines (NASDAQ:RVMD) Stock
September 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31003491
Corient Private Wealth LP Acquires New Stake in Revolution Medicines, Inc. $RVMD
September 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-corient-private-wealth-lp-acquires-new-stake-in-revolution-medicines-inc-rvmd-2026-09-04/
J.P. Morgan Sticks to Their Buy Rating for Revolution Medicines (RVMD)
September 3, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/RVMD/pressreleases/4421915/jp-morgan-sticks-to-their-buy-rating-for-revolution-medicines-rvmd/
Revolution Medicines Highlights NEJM Publication Of RASONQUE Lung Cancer Data
September 3, 2026  |  rttnews.comhttps://www.rttnews.com/3688083/revolution-medicines-highlights-nejm-publication-of-rasonque-lung-cancer-data.aspx
Revolution Medicines (NASDAQ:RVMD) Director Lorence Kim Sells 56,000 Shares
September 3, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-rvmd-insider-buying-and-selling-2026-09-03/
New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines' RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer
September 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/02/3355564/0/en/new-england-journal-of-medicine-publishes-phase-1-2-clinical-data-on-revolution-medicines-rasonque-daraxonrasib-in-metastatic-non-small-cell-lung-cancer.html
Insider Selling: Revolution Medicines (NASDAQ:RVMD) Director Sells $11,381,440.00 in Stock
September 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-selling-revolution-medicines-nasdaq-rvmd-director-sells-1138144000-in-stock-2026-09-02/
Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Revolution Medicines (RVMD)
September 2, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/RVMD/pressreleases/4401327/analysts-offer-insights-on-healthcare-companies-incyte-incy-and-revolution-medicines-rvmd/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Illustration showing Hims & Hers logo and app connected through a security checkpoint icon to the Visa logo and card.
Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
By Jeffrey Neal Johnson | August 24, 2026
Illustration of a glowing digital shield and lock blocking red virus icons in a server data center.
3 Ways to Invest in Cybersecurity Through ETFs
By Dan Schmidt | August 20, 2026
IonQ logo displayed within an illuminated glass chamber surrounded by a futuristic space-themed backdrop.
IonQ’s Space Contract Points to a New Frontier for Quantum Investors
By Nathan Reiff | August 19, 2026
Illustration of a glass globe surrounded by gold coin stacks, symbolizing global financial markets and investment.
This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
By Jessica Mitacek | August 17, 2026
Gold-colored concept electric vehicle with a smooth, minimalist body parked outdoors near a building and tree.
Ride-Share Reckoning: Tesla Drives Into Uber's Lane
By Jeffrey Neal Johnson | September 7, 2026
Alnylam Pharmaceuticals stock logo

Alnylam Pharmaceuticals NASDAQ:ALNY

$248.68 +1.17 (+0.47%)
Closing price 04:00 PM Eastern
Extended Trading
$250.12 +1.44 (+0.58%)
As of 06:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Madrigal Pharmaceuticals stock logo

Madrigal Pharmaceuticals NASDAQ:MDGL

$534.49 +1.37 (+0.26%)
Closing price 04:00 PM Eastern
Extended Trading
$534.42 -0.07 (-0.01%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Natera stock logo

Natera NASDAQ:NTRA

$328.93 +2.79 (+0.86%)
Closing price 04:00 PM Eastern
Extended Trading
$326.00 -2.94 (-0.89%)
As of 06:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Revolution Medicines stock logo

Revolution Medicines NASDAQ:RVMD

$203.77 +0.42 (+0.21%)
Closing price 04:00 PM Eastern
Extended Trading
$203.25 -0.52 (-0.25%)
As of 06:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas